Dr. Sboul is the Group Lead of Pharmaceutical Industry as part of the National Team

responsible for developing Jordan’s Economic Modernization Vision 2023-2033, she

is also a member of the Board of Jordan Food and Drug Administration JFDA, a

member of Hashemite University Board of Trustees, the Vice Chair of the Steering

Committee for the Jordan Pharmaceutical Center of Excellence, member of the

Advisory Council of Pharmacy School at Jordan University of Science & Technology.

Dr. Sboul has also served as a Member of several Boards, including the Higher

Education Council and The Higher Committee for Drugs & Pharmacy, the Scientific

Research Support Fund, the Fund for Employment, Technical, Vocational Education

& Training (E-TVET Fund), the University of Science & Technology Council, the

Council of Pharmacy School at Jordan University.

At international level, Dr. Sboul was the Chair of the International Generic &

Biosimilar Medicines Association IGBA in 2020.

She was also a member of the USP Council of Convention, the Chair of the USP

Convention Membership Committee & the Chair of USP MENA Regional Chapter.

In her current and previous roles, Ms. Sboul is actively engaged in enhancing the

regulatory landscape for pharmaceuticals to improve access to quality, safe &

effective medicines and support local pharmaceutical industry.

Dr. Sboul received her MBA from Jordan University in 2000 and received her B.A in

Pharmacy from Yarmouk University. She was the first Association Executive from

Jordan to receive the Certified Association Executive Certificate from the American

Society for Association Executives in 2005.

Nabeela Ahmed Memon regulatory affairs pharmacist in the Kingdom of Bahrain with nearly a decade of progressive experience at the National Health Regulatory Authority (NHRA).

Currently serves as Head of Registration & Pricing and holds the additional responsibility of Chief of Pharmacy & Pharmaceutical Products Regulation department, leading national oversight of medicine registration, pricing, and regulatory compliance.

Leads national operations for pharmaceutical product registration and pricing, overseeing innovative, generic, and non-registered medicine portfolios in alignment with GCC and international standards.

Spearheaded the digital transformation of medicine registration through full implementation of the “Adweya” system, reducing review timelines by 35% and enhancing regulatory efficiency.

Deputy Chairperson of the Pharmaceutical Products Licensing Committee and represents Bahrain in regional GCC regulatory harmonization and GMP initiatives.

Recipient of the prestigious Prince Salman bin Hamad Medical Merit Award in recognition of her leadership and outstanding contribution during Bahrain’s national COVID-19 response.

Mr. Marwan Zeidan is leading EVOTEQ’s business development and client relationships, responsible to drive growth while maintaining client satisfaction.

He has over 25 years of rich experience that has encompassed various disciplines in business development, sales and delivery across complex IT/OT digital solutions, public sector offerings, and smart buildings/cities. Prior to joining EVOTEQ, he was leading TASMU, Qatar’s national smart city platform within the Ministry of Communications and Information Technology.

He held various roles in Schneider Electric, supporting customers in their digital transformation, leveraging the best in Operational Technology solutions with advanced Information Technology. He was also an Associate Partner with IBM leading Watson IoT Services for MEA, and a Senior Manager with Cisco Systems leading consulting and solution selling for Smart Cities in Europe and MEA. He also held positions with consulting companies that include Accenture and Deloitte & Touche.

Mr. Marwan graduated from the American University of Beirut with a degree in Computer and Communications Engineering.

Dr. Rawya is a clinical pharmacist with broad Medical and Pharmaceutical knowledge, experience in various aspects of the Pharmaceutical Industry especially Medical Affairs, Regulatory Affairs and Pharmacovigilance, as well as knowledge and experience in the research field. She has a M.Sc. Clinical Pharmacy (with Distinction) – Queen’s University, UK.
Dr. Rawya began her career at Hikma Pharmaceuticals, Jordan since 1998 till 1999, and she is currently the Regulatory Affairs & Medical Affairs Director at Gulf Pharmaceutical Industries (Julphar), Ras Al Khaimah, United Arab Emirates since 2020 – to the present date.
In her role in Regulatory affairs, she displays and actions leadership in all aspects of Regulatory Affairs for company product portfolio of generics and novel products, including product development and submissions.
She is also an expert in defining the strategic regulatory direction for pipeline development and global launch excellence for a significant dedicated R&D budget. In addition, Dr. Rawya is knowledgeable of partnering with R&D and Global Strategic Marketing leaders as well another functional leader to develop and implement strategy for pipeline development and global launch excellence.

With over 23 years of experience in the biopharmaceutical industry, Varma Bhupathiraju is a recognized leader in global regulatory affairs, specializing in the development and approval of biologics. He has played a pivotal role in securing approvals for multiple biological products, including biosimilars and vaccines, across key global markets such as LATAM, MENA, CIS, AFRICA, and APAC. Notably, he pioneered the first-ever US FDA approval for a vaccine candidate from an Indian manufacturer.

Varma has successfully obtained regulatory approvals in over 100 countries and secured GMP accreditations from leading regulatory agencies, including ANVISA-Brazil, COFEPRIS-Mexico, ANMAT-Argentina, ISP-Chile, SAHPRA-South Africa, NPRA-Malaysia, DAV-Vietnam, EDA-Egypt, NAFDAC-Nigeria, TMDA-Tanzania, NDA-Uganda, MCAZ-Zimbabwe, WHO, ensuring alignment to facilitate market access. Additionally, he has been instrumental in streamlining regulatory approval processes in India.

Currently, Varma leads the regulatory team for Emerging Markets and India, driving the company’s mission to expand patient access to affordable biologics.

Mr. Mete Karaca serves as an Executive Board Member at Tiga Healthcare Technologies, where he spearheads Business Development initiatives, driving the company’s growth and strategic partnerships in the healthcare IT landscape. With a robust technical foundation stemming from a bachelor’s degree in Electrical and Electronics Engineering, Mr. Karaca combines analytical precision with innovative problem-solving skills, enabling him to address complex challenges in the ever-evolving healthcare technology sector.

To complement his technical expertise, Mr. Karaca pursued a master’s degree in Engineering Management, where he cultivated advanced project management capabilities and honed his leadership acumen. This multidisciplinary background has positioned him as a dynamic leader who seamlessly integrates technical knowledge with strategic vision, delivering transformative results across a wide range of projects.

Over nearly two decades, Mr. Karaca has led and delivered numerous health IT projects across the globe, with notable experience, especially in national-scale healthcare information systems. His expertise spans key domains such as Healthcare Interoperability, Health Information Exchange, Personal Health Record (PHR), Central e-Prescription, Pharmaceutical Track and Trace System and Hospital Information System (HIS), solidifying his reputation as a trusted leader in transforming healthcare infrastructure on a national level. His work in the GCC region has been particularly impactful, showcasing his ability to manage multi-stakeholder collaborations with public healthcare authorities, regulators and leading organizations. This extensive experience underscores his versatility and expertise in complex, high-impact projects with precision and efficiency.

Mr. Karaca’s profound understanding of the intersection between healthcare and technology has enabled him to advance innovation within the industry. His leadership continues to shape projects that merge cutting-edge technologies with patient-centric solutions, setting new benchmarks for efficiency and effectiveness in healthcare delivery. As a forward-thinking leader, Mr. Karaca remains dedicated to driving progress and fostering meaningful change in healthcare IT worldwide.

Dr. Fatima Zaid Abu Zanat is a pioneering leader in pharmaceutical and healthcare industries, with over 17 years of experience ensuring timely patient access to innovative therapies in some of the world’s most dynamic emerging markets. As Regional Director of Regulatory Affairs & Scientific Office at Ipsen Pharma, she blends scientific rigor with strategic leadership, while passionately championing the evolution of regulatory affairs professional into a creative, purpose-driven business partner within Ipsen, partners and beyond.

A pharmacist by training and R&D scientist by education, Dr. Abu Zanat holds three international research publications, two of which are based on her groundbreaking MSc Pharmaceutical Technology thesis on a novel co-drug for dyslipidemia. She also holds the prestigious RAPS Dual Regulatory Affairs Diploma and Certificate. Her contributions to the broader industry include active roles with associations such as RAPS, PhRMA MEA and formerly Mecomed. Her voice and vision continue to be sought after at major, regulatory forums, where she regularly contributes as a speaker and panel moderator.

Her exceptional contributions have earned her prestigious accolades, including the most recent Award of 2025 Global Women Power Leaders for the category of Regulatory Excellence Across Borders, 2023 GCC Regulatory Affairs “Women of the Middle East” Award, 2022 nomination among Ipsen’s top Women of the Year and DUPHAT 2012 3rd Best Professional Poster Award. As a mentor and recognized leader, Dr. Abu Zanat continues to shape the future of regulatory affairs – empowering the next generation to lead with purpose, innovation and integrity.

A pharmacist and data expert with an MSc in Clinical Pharmacy from the University of Jordan. She currently serves as the Regulatory & Clinical Data Content Lead at Pi Pharma, where she has spent the past four years guiding a high-performing team to deliver credible, evidence-based content across the healthcare and pharmaceutical space. With an earlier four-year tenure in academia across universities and colleges, Abeer brings a rare blend of scientific rigor and real-world industry insight. Her work centers on transforming complex clinical and regulatory information into actionable, data-driven insights that support smarter decisions, compliance, and improved healthcare outcomes. Passionate about quality, analytics, and clarity, she builds content frameworks that align regulatory standards with practical stakeholder needs bridging science, policy, and patient impact.